Luye Pharma Group (LYPHF) Stock Price, News & Analysis

Company Overview

Luye Pharma Group is a China-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines. The company focuses on innovative and specialty therapies, with research and product activities spanning central nervous system disorders, oncology, cardiovascular disease, metabolic conditions and gastrointestinal illnesses.

Luye Pharma develops medicines using technologies such as long-acting injectable formulations, transdermal patches and other controlled-release drug-delivery systems. Its portfolio includes treatments for conditions such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease and cancer, as well as products in cardiovascular and other therapeutic areas. The company markets both internally developed products and licensed or acquired medicines.

Founded in 1997, Luye Pharma has expanded from its roots in China into an international pharmaceutical business. Its products and operations serve markets in China, the United States, Europe and other regions, supported by research, manufacturing and commercial capabilities in multiple countries. The company is led by founder and Chairman Liu Dianbo and is listed on the Hong Kong Stock Exchange under the symbol 02186; its shares also trade over the counter in the United States under the symbol LYPHF.

Key Stats

• Today's Range: $0.27 to $0.27
• 50-Day Range: $0.27 to $0.27
• 52-Week Range: $0.20 to $0.33
• Volume: N/A
• Average Volume: 1.23 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:LYPHF
• CIK: N/A
• Web: www.luye.cn
• Phone: +865356717618
• Fax: N/A
• Employees: 5,221
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A